Home > Insider Trading > Filing (0001209191-23-004136)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1718852	Prometheus Biosciences Inc.	RXDX	Pharmaceutical Preparations (2834)	814282653

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1749623	C. Mark Mckenna	C/O Prometheus Biosciences, Inc. 3050 Science Park Road San Diego CA 92121	Chairman, President & Ceo	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2023-01-17	25,000	$2.90	80,144	No	4	M	Direct
Common Stock	Disposition	2023-01-17	25,000	$118.99	55,144	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2023-01-17	25,000	$0.00	25,000	$2.90

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
333,633		2029-11-06	No	4	M	Direct

Footnotes

The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person in April 2022.
The price reported in Column 4 is a weighted average price. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
25% of the shares subject to the option vested and became exercisable on September 9, 2020, and 1/48th of the shares subject to the option shall vest monthly thereafter, subject to the Reporting Person's continued service with the Issuer through each vest date.